Positive data on depression treatment based on a drug related to the psychedelic DMT is breathing life into shares of biotechs working on psychedelic medicines, after years of disappointments. Just as ...
The bipolar depression market is anticipated to increase during the forecast period (2026--2036), owing to the rise in the launch of emerging therapies such as Azetukalner (Xenon Pharmaceuticals), ...
The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson‘s Caplyta as an add-on treatment for adults with major depressive disorder. Following the FDA’s Nov. 5 decision ...
Structurally novel neurokinin-1 receptor inhibitors reduce depressive-like behavior and brain inflammation in mice SEOUL, South Korea, Jan. 14, 2026 /PRNewswire/ --Researchers report that redesigning ...
A mind-altering medication related to the club drug Special K won U.S. approval Tuesday for patients with hard-to-treat depression, the first in a series of long-overlooked substances being ...
-- Reposted from the online magazine, "The Trauma & Mental Health Report" The pharmaceutical industry grosses over $300 billion a year in psychotropic medication sales. Included in this figure are ...
An experimental depression drug that joined the Neurocrine Biosciences pipeline as part of a broader package from Takeda Pharmaceutical failed to meet the main goal of a mid-stage clinical trial. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results